Clinical trials: Prostate Cancer Stage
Prostate Cancer
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer.
- Trial name
- NCT00895466
- Testing
- PEP-223/CoVaccine HT
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Pepscan Therapeutics
Breast Cancer, Depression
Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer
RATIONALE: A multimedia educational program may help patients with newly diagnosed prostate cancer and breast cancer reduce distress, make informed treatment decisions, and improve quality of life.
- Conditions
- Breast Cancer, Depression, Long-term Effects of Cancer Treatment, Prostate Cancer
- Trial name
- NCT00830635
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 3 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Prostatic Neoplasms
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate staging of the disease at the time point of diagnosis is important.
- Trial name
- NCT02076503
- Testing
- PET-MR 18f-FACBC, histology (gold standard)
- Where
- Norway
- Volunteers
- 28 people
- Sponsor
- St. Olavs Hospital
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men…
- Trial name
- NCT00002760
- Testing
- ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
RATIONALE: New imaging procedures such as CT-on-rails™ may improve the ability to pinpoint the location of the tumor and decrease radiation therapy damage to healthy tissue.
- Trial name
- NCT00084526
- Testing
- computed tomography, ultrasound imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fox Chase Cancer Center
Prostatic Neoplasms
Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Prostatic Neoplasms.
- Trial name
- IRE (NCT02430649)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with…
- Trial name
- NCT00004014
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Anemia, Cardiovascular Complications
Prostate Adenocarcinoma TransCutaneous Hormones
RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term…
- Conditions
- Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis
- Trial name
- PATCH (NCT00303784)
- Testing
- Goserelin, Estradiol
- Where
- 32 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- University College, London
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00258466
- Testing
- radiation therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00943956
- Testing
- bicalutamide, everolimus, leuprolide acetate
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Prostate Cancer
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in…
- Trial name
- NCT00667888
- Testing
- Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003026
- Testing
- bicalutamide, flutamide, triptorelin
- Where
- 17 sites in Belgium, Israel and 5 more
- Volunteers
- 966 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer
RATIONALE: Learning about changes in DNA over time in patients with prostate cancer undergoing diet and lifestyle changes may help doctors learn about the long-term effects of these changes on disease progression.
- Trial name
- NCT00739791
- Testing
- exercise intervention, gene expression analysis, polymerase chain reaction
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose rate (HDR) brachytherapy.
- Trial name
- NCT00807820
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech